For instance, C-reactive protein (CRP), a marker of inflammation, is known to be involved in the pathophysiology of both CVD and cancer.13,14 Recently, the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provided evidence that anti-inflammatory therapy targeting interleukin (IL)-1b (of the CRP/IL-6/IL-1 axis) in individuals with pre-existing CVD not only lowered the risk of developing recurrent cardiovascular events15 but also reduced the risk of developing cancer events.16 This evidence concerns the gene CRP and deep vein thrombosis.